PMID- 37072577
OWN - NLM
STAT- MEDLINE
DCOM- 20230420
LR  - 20231120
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Apr 18
TI  - Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated 
      aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes 
      mellitus.
PG  - 6302
LID - 10.1038/s41598-023-33417-3 [doi]
LID - 6302
AB  - Type 2 diabetes mellitus (T2DM) is one of the most common diseases, that managed 
      by several medications such as Glimepiride and Dapagliflozin. This study aims to 
      compare the effects of Dapagliflozin versus Glimepiride on glycemic control, 
      insulin resistance, and biomarkers as (extracellular domain of insulin regulated 
      aminopeptidase) IRAPe, (interleukin-34) IL-34, and (N-terminal pro b-type 
      natriuretic peptide) NT-proBNP. This study included 60 type 2 diabetic patients, 
      who are randomized to receive either Glimepiride 4 mg/day (group 1) or 
      Dapagliflozin 10 mg/day (group 2). Blood samples were collected at baseline and 
      after 3 months of treatment for biochemical analysis. Additionally, HOMA-IR is 
      calculated. After 3 months of receiving the intervention, there is no significant 
      difference between the effects of Glimepiride and Dapagliflozin on FBG, PPBG, 
      HbA1C%, fasting insulin, and HOMA-IR. The difference between both groups is 
      significant for IL-34 (p = 0.002) and non-significant for IRAPe (p = 0.12) and 
      NT-Pro BNP (p = 0.68). Both Glimepiride and Dapagliflozin significantly improve 
      glycemic control, and HOMA-IR with no significant difference between them. Both 
      drugs significantly improved the level of NT-proBNP. Dapagliflozin has a 
      borderline significant effect on IRAPe but not IL-34, and Glimepiride has 
      significant effect on IL-34 but not IRAPe. Clinical Trial Registration: This 
      trial was registered on clinicaltrial.gov (NCT04240171).
CI  - (c) 2023. The Author(s).
FAU - Zekry, Rania
AU  - Zekry R
AD  - Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, 
      Damanhour University, Damanhour, 22514, Egypt.
FAU - Omran, Gamal A
AU  - Omran GA
AD  - Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour, 
      22514, Egypt.
FAU - El-Gharbawy, Nashwa M
AU  - El-Gharbawy NM
AD  - Diabetes and Endocrinology Unit, Department of Internal Medicine, Tanta 
      University, Tanta, Egypt.
FAU - Werida, Rehab H
AU  - Werida RH
AUID- ORCID: 0000-0002-5983-3993
AD  - Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, 
      Damanhour University, Damanhour, 22514, Egypt. rehabwrieda@pharm.dmu.edu.eg.
LA  - eng
SI  - ClinicalTrials.gov/NCT04240171
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230418
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 6KY687524K (glimepiride)
RN  - 0 (Insulin)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 0 (Blood Glucose)
RN  - 0 (Interleukins)
SB  - IM
EIN - Sci Rep. 2023 Oct 4;13(1):16687. PMID: 37794064
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Insulin/therapeutic use
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Blood Glucose
MH  - Interleukins/therapeutic use
MH  - Treatment Outcome
MH  - Drug Therapy, Combination
PMC - PMC10113266
COIS- The authors declare no competing interests.
EDAT- 2023/04/19 00:41
MHDA- 2023/04/20 06:42
PMCR- 2023/04/18
CRDT- 2023/04/18 23:27
PHST- 2022/10/07 00:00 [received]
PHST- 2023/04/12 00:00 [accepted]
PHST- 2023/04/20 06:42 [medline]
PHST- 2023/04/19 00:41 [pubmed]
PHST- 2023/04/18 23:27 [entrez]
PHST- 2023/04/18 00:00 [pmc-release]
AID - 10.1038/s41598-023-33417-3 [pii]
AID - 33417 [pii]
AID - 10.1038/s41598-023-33417-3 [doi]
PST - epublish
SO  - Sci Rep. 2023 Apr 18;13(1):6302. doi: 10.1038/s41598-023-33417-3.